You just read:

German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx® (lenvatinib) in Treatment of Advanced Renal Cell Carcinoma (RCC)

News provided by

Eisai

27 Mar, 2017, 13:32 BST